Table 3.
Median time‐to‐event results by baseline renal function according to treatment regimens, rwTTD and OS
| Normal | Moderate or severe dysfunction | |||
|---|---|---|---|---|
| Outcome and treatment regimen | Events/n | Median (95% CI), mo | Events/n | Median (95% CI), mo |
| rwTTD of ICI | ||||
| All | 1,299/1,838 | 2.5 (2.3–2.8) | 37/46 | 2.1 (1.6–3.2) |
| Ipilimumab | 545/575 | 2.1 (2.1–2.1) | 14/15 | 2.1 (1.0–3.1) |
| Ipi + nivolumab | 246/386 | 4.0 (3.3–5.5) | 1/3 | 29.6 (n/a–n/a) |
| Nivolumab | 195/361 | 6.6 (5.5–8.5) | 9/13 | 3.3 (0.03–n/a) |
| Pembrolizumab | 313/516 | 5.5 (4.7–7.5) | 13/15 | 2.1 (1.5–n/a) |
| OS | ||||
| All | 738/1,838 | 22.1 (19.9–25.5) | 35/46 | 8.2 (4.2–12.9) |
| Ipilimumab | 345/575 | 15.9 (14.0–18.5) | 13/15 | 8.4 (3.1–n/a) |
| Ipi + nivolumab | 125/386 | 29.4 (20.3 –n/a) | 1/3 | 29.9 (n/a–n/a) |
| Nivolumab | 109/361 | 33.0 (19.6–n/a) | 8/13 | 8.5 (2.6–n/a) |
| Pembrolizumab | 159/516 | 28.8 (23.2–n/a) | 13/15 | 5.0 (2.8–n/a) |
For the median estimate, n/a occurred when <50% of the cohort had the event of interest. For 95% CI bounds, this occurred either when there were too few events or because the upper confidence limit is <50%.
Abbreviations: CI, confidence interval; Ipi, ipilimumab; OS, overall survival; n/a, result not calculable; rwTTD, real‐world time to treatment discontinuation.